AVANIR Pharmaceuticals (NASDAQ:AVNR)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

Recs

1
Player Avatar zzlangerhans (99.70) Submitted: 1/16/2013 7:01:46 AM : Underperform Start Price: $3.16 AVNR Score: +9.00

Nuedexta revenues have been increasing steadily, but not enough to justify a rebound from 2.16 to 3.16 and a market cap of 432M despite an ongoing double digit quarterly burn and only 70M in the bank as of the end of Q3. I suspect traders are looking for positive news on Nuedexta from the CHMP, but European approval is a notorious false start for companies with products that are already approved in the US. Other pipeline compounds remain in early clinical development.

Featured Broker Partners


Advertisement